Trial ID or NCT#

NCT02000102

Status

NOT RECRUITING

Purpose

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Theodore Leng, MD, FACS
Retina specialist, Ophthalmologic surgeon, Cataract specialist, Ophthalmologist
Assistant Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine at the Stanford University Medical Center

Contact us to find out if this trial is right for you.

CONTACT

Theodore Leng, MD
(650) 723-6995